Synapse - Tiffany Traina

Search Within

Tiffany A Traina

Results (250)

OncoKB: Annotation of the oncogenic effect and treatment implications of somatic mutations in cancer

Meeting Abstract

Chakravarty, D.; Phillips, S. M.; Gao, J.; Kundra, R.; Zhang, H.; Rudolph, J. E.; Yaeger, R. D.; Soumerai, T.; Nissan, M. H.; Chandarlapaty, S.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Phase (Ph) 1 study of oral seviteronel (VT-464), a dual CYP17-Lyase (L) inhibitor and androgen receptor (AR) antagonist, in patients (pts) with advanced AR plus triple negative (TNBC) or estrogen receptor (ER) plus breast cancer (BC)

Meeting Abstract

Bardia, A.; Dacosta, N. A.; Gabrail, N. Y.; Lemon, S.; Danso, M. A.; Ali, H. Y.; Fleming, R. A.; Kurman, M. R.; Eisner, J. R.; Moore, W. R.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Phase I/II trial of palbociclib in combination with bicalutamide for the treatment of androgen receptor (AR)(+) metastatic breast cancer (MBC): Pharmacokinetics (PK)

Meeting Abstract

Gucalp, A.; Corben, A.; Patil, S.; Boyle, L. A.; Hudis, C.; Traina, T. A.
Annals of Oncology (2016)

Fulltext@MSK | Save

Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy

Meeting Abstract

Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M.; Goldfarb, S.; more...
Annals of Oncology (2016)

Fulltext@MSK | Save

Targeting the androgen receptor in triple-negative breast cancer

Journal Article

Gucalp, A.; Traina, T. A.
Current Problems in Cancer (2016)

Fulltext@MSK | Save

Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: Overall survival and updated progression-free survival results from a phase II study

Journal Article

Smyth, L. M.; Iyengar, N. M.; Chen, M. F.; Popper, S. M.; Patil, S.; Wasserheit-Lieblich, C.; Argolo, D. F.; Singh, J. C.; Chandarlapaty, S.; Sugarman, S. M.; more...
Breast Cancer Research and Treatment (2016)

Fulltext@MSK | Save

MDV3100-08: A phase 1 study evaluating the safety and pharmacokinetics of enzalutamide plus fulvestrant in women with advanced hormone receptor-positive breast cancer

Meeting Abstract

Elias, A. D.; Burris, H. A.; Patel, M. R.; Schwartzberg, L. S.; Richer, J. K.; Kavalerchik, E.; Stopatschinskaja, S.; Gibbons, J.; Markova, D.; Steinberg, J. L.; more...
Cancer Research (2016)

Fulltext@MSK | Save

Androgen receptor (AR) mutations in a cohort of patients with breast cancer (BC) who have undergone tumor genomic profiling

Meeting Abstract

Gucalp, A.; Proverbs-Singh, T. A.; Razavi, P.; Chandarlapaty, S.; Patil, S.; Ross, D. S.; Zehir, A.; Baselga, J.; Hudis, C. A.; Traina, T. A.
Cancer Research (2016)

Fulltext@MSK | Save

Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC

Meeting Abstract

Bardia, A.; Diamond, J. R.; Mayer, I. A.; Starodub, A. N.; Moroose, R. L.; Isakoff, S. J.; Ocean, A. J.; Guarino, M. J.; Berlin, J. D.; Messersmith, W. A.; more...
Cancer Research (2016)

Fulltext@MSK | Save

Phase 2 study of dose-dense doxorubicin and cyclophosphamide followed by eribulin mesylate with or without prophylactic growth factor for adjuvant treatment of early-stage breast cancer

Meeting Abstract

Cadoo, K.; Kaufman, P. A.; Hudis, C.; Chang, C.; Berrak, E.; Song, J.; Seidman, A. D.; Traina, T. A.
Cancer Research (2016)

Fulltext@MSK | Save